Literature DB >> 22920904

Druggability of mortalin for cancer and neuro-degenerative disorders.

Custer C Deocaris1, Wen-Jing Lu, Sunil C Kaul, Renu Wadhwa.   

Abstract

Mortalin is a member of Hsp70 family of stress chaperones. It was first identified as a protein involved in the senescence of mouse cells. Genetic studies revealed that there are two mouse mortalin alleles coding for two proteins (mot-1 and mot-2) that differ in only two amino acids in the carboxy-terminus, but have contrasting activities. Whereas mot-1 accelerated senescence, mot-2 extended the lifespan of mouse cells in culture. In human cells, only one kind of mortalin protein has been identified so far and is shown to be functionally equivalent to mouse mot-2. Whereas mortalin is enriched in cancer cells and contributes to carcinogenesis, the old age brain disorders show its deficiency. As we demystify its deux de machina, accumulating evidence reveal that mortalin may be "druggable" bidirectionally to either treat cancer or neuro-degenerative disorders.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22920904

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  14 in total

1.  Biophysical Consequences of EVEN-PLUS Syndrome Mutations for the Function of Mortalin.

Authors:  Mitchell A Moseng; Jay C Nix; Richard C Page
Journal:  J Phys Chem B       Date:  2019-04-12       Impact factor: 2.991

2.  Stress chaperone mortalin regulates human melanogenesis.

Authors:  Renu Wadhwa; Didik Priyandoko; Ran Gao; Nashi Widodo; Nupur Nigam; Ling Li; Hyo Min Ahn; Chae-Ok Yun; Nobuhiro Ando; Christian Mahe; Sunil C Kaul
Journal:  Cell Stress Chaperones       Date:  2016-04-07       Impact factor: 3.667

Review 3.  Why is Mortalin a Potential Therapeutic Target for Cancer?

Authors:  A-Rum Yoon; Renu Wadhwa; Sunil C Kaul; Chae-Ok Yun
Journal:  Front Cell Dev Biol       Date:  2022-06-29

Review 4.  Molecular Chaperones in Cancer Stem Cells: Determinants of Stemness and Potential Targets for Antitumor Therapy.

Authors:  Alexander Kabakov; Anna Yakimova; Olga Matchuk
Journal:  Cells       Date:  2020-04-06       Impact factor: 6.600

5.  Structural studies of UBXN2A and mortalin interaction and the putative role of silenced UBXN2A in preventing response to chemotherapy.

Authors:  Sanam Sane; Ammara Abdullah; Morgan E Nelson; Hongmin Wang; Subhash C Chauhan; Samuel S Newton; Khosrow Rezvani
Journal:  Cell Stress Chaperones       Date:  2015-12-04       Impact factor: 3.667

6.  Targeting Mortalin by Embelin Causes Activation of Tumor Suppressor p53 and Deactivation of Metastatic Signaling in Human Breast Cancer Cells.

Authors:  Nupur Nigam; Abhinav Grover; Sukriti Goyal; Shashank P Katiyar; Priyanshu Bhargava; Pi-Chao Wang; Durai Sundar; Sunil C Kaul; Renu Wadhwa
Journal:  PLoS One       Date:  2015-09-16       Impact factor: 3.240

7.  Mitochondria chaperone GRP75 moonlighting as a cell cycle controller to derail endocytosis provides an opportunity for nanomicrosphere intracellular delivery.

Authors:  Zhihui Gao; Xiuran Niu; Qing Zhang; Hang Chen; Aiai Gao; Shanshan Qi; Rong Xiang; Mattias Belting; Sihe Zhang
Journal:  Oncotarget       Date:  2017-04-19

8.  Critical Role of Mortalin/GRP75 in Endothelial Cell Dysfunction Associated with Acute Lung Injury.

Authors:  Antony Leonard; Pei Yi Su; David I Yule; Arshad Rahman; Fabeha Fazal
Journal:  Shock       Date:  2020-08       Impact factor: 3.533

9.  The clinicopathological significance of Mortalin overexpression in invasive ductal carcinoma of breast.

Authors:  Haidan Jin; Meiying Ji; Liyan Chen; Qixiang Liu; Shuanlong Che; Ming Xu; Zhenhua Lin
Journal:  J Exp Clin Cancer Res       Date:  2016-03-09

Review 10.  UBXD Proteins: A Family of Proteins with Diverse Functions in Cancer.

Authors:  Khosrow Rezvani
Journal:  Int J Mol Sci       Date:  2016-10-14       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.